

Nivo/Ipi (nivolumab and ipilimumab) CheckMate 227

### PRELIMINARY SCORE

**CURATIVE**



**NON-CURATIVE**



### ADJUSTMENTS

**Quality of life**



**Serious and disabling adverse effects**



**Other adjustments**



Nivo/Ipi (nivolumab and ipilimumab) CheckMate 227

### FINAL SCORE

**CURATIVE**



Overall Survival / Disease-Free Survival / Pathological Complete Response

**NON-CURATIVE**




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

**INFORMATION**

Tumour type: Thoracic Malignancies  
 Therapeutic Indication: First-line treatment for patients with mNSCLC expressing PD-L1 (≥1%) with no EGFR or ALK genomic tumour aberrations  
 Experimental Arm: Nivo/Ipi (nivolumab and ipilimumab)  
 Control Arm: Chemotherapy

